Nebenwirkungen · Vimkunya
VIMKUNYA suspension for injection in pre-filled syringe Chikungunya vaccine (recombinant, adsorbed) · Abschnitt 4.8 · PDF-Seite 5
HOS-147636 · Präparat HOS-099702
The tabulated summary of the adverse reactions following administration of VIMKUNYA (Table 1) is based on an analysis of the pooled safety data gathered from three completed phase 2 studies and two completed phase 3 studies on 3 522 participants ≥ 12 years old who received VIMKUNYA. Of these, 3 141 individuals received a single 40 micrograms dose of VIMKUNYA. These participants were followed up for serious adverse events over the entire study period of 182 days.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-24T10:41:41Z · SHA-256 d7d4b80caf46d09a90e22a10073a8cf15f65e587ba53cbd5031223867370bddf · Passage 76c5aad351b7761dd749f1706b241ba5eb1a0a729092fdac644053f145d9d2f4 · Zeichen 332–798 im Abschnitt